

FILE NO.A34054-PCT-USA 072975.0110
PATENT

REMARKS

This paper is being filed in response to the telephone calls from Examiner Christian Fronda received by Rochelle K. Seide on June 20, 2002 and June 27, 2002. Applicants respectfully request further consideration of the above-identified application in light of the amendments and remarks presented herein.

Claims 1, 3, 6-11, and 15 are pending. Claims 1, 10, and 15 have been amended. Rewritten claims appear in the preceding "IN THE CLAIMS" section. Attached hereto is a marked-up version of the changes made by the instant amendment captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE" and is included pursuant to 37 C.F.R. §1.121(c)(ii). Should any discrepancies be discovered, the version presented in the preceding "IN THE CLAIMS" section shall take precedence.

Claims 1, 10, and 15 have been amended to substitute "polypeptide" with "protein" simply for consistency. This substitution is not to be construed as narrowing the scope of the claims since the specification supports the interchangeability of these terms at page 3, lines 13-15 of the specification.


Applicants thank the Examiner for his calls regarding the above-identified application. The Examiner indicated in his telephone call on June 20, 2002 to Rochelle K. Seide that claims as amended to recite lysozyme activity would be allowable. The Examiner further indicated that no restriction requirement would be imposed with respect to claim 15. Applicants, therefore, respectfully request prompt issuance of a Notice of Allowance for all pending claims.

FILE NO. A34054-PCT-USA 072975.0110
PATENT

Applicants believe that no fees are due with this response. Any required fees may be charged to Deposit Account No. 02-4377. Two copies of this sheet are enclosed.

Respectfully submitted,

June 27, 2002



Rochelle K. Seide
PTO Reg. No. 32,300

Attorney for Applicant
BAKER BOTTS, L.L.P.
30 Rockefeller Plaza
New York, NY 10112
(212) 408-2626

Enclosure

FILE NO.A34054-PCT-USA 072975.0110
PATENT

VERSION WITH MARKINGS TO SHOW CHANGES MADE

This marked-up version was prepared with DeltaView software (v2.5.163). The reference version of the claims was that presented in Applicants' Amendment filed April 15, 2002. In this section, added text is marked with double underlining. *e.g.* added text, and deleted text is marked by a single strikethrough, *e.g.* ~~deleted text~~.

IN THE CLAIMS

Claim 1 has been **amended** as follows:

1. An isolated DNA molecule comprising a nucleotide sequence encoding a ~~polypeptide~~protein comprising the amino acid sequence of SEQ ID NO:4 or of amino acids 19-146 of SEQ ID NO:4 wherein said protein has lysozyme activity.

Claim 10 has been **amended** as follows:

10. A method for producing a LYC3 protein having lysozyme activity comprising:
 - (a) introducing an expression vector for production of LYC3 protein, said vector comprising a nucleotide sequence encoding a ~~polypeptide~~protein having the amino acid sequence of SEQ ID NO:4 or of amino acids 19-146 of SEQ ID NO:4, wherein said nucleotide sequence is operably linked to at least one expression control sequence, into a host cell, thereby forming a recombinant host cell;
 - (b) culturing the recombinant host cell of (a) under conditions suitable for expression of the DNA molecule encoding the ~~polypeptide~~protein, such that LYC3 protein is produced;and

FILE NO.A34054-PCT-USA 072975.0110
PATENT

(c) isolating the LYC3 protein so produced.

15. An isolated LYC3 ~~polypeptide~~protein having lysozyme activity comprising a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:4 and amino acids 19-146 of SEQ ID NO:4.